This would be outside the scope of available data and current FDA approval. Both CodeBreaK100 and CodeBreaK 200 (presented at ESMO) included only patients previously treated with either chemotherapy, immunotherapy, or both. I would generally stick to standard first line options for these patients, e...

I would not. Immunotherapy (in some form) remains the standard first-line treatment for KRAS G12C.  In other subsets, like EGFR and ALK, targeted therapy is the first-line standard because immunotherapy is largely ineffective, and targeted therapy after immunotherapy is more toxic (at least fo...

I would prioritize an ICI for PD-L1 50% or greater and save sotorasib for second line. For patients with PD-L1 <1%, I would recommend sotorasib first-line, given the low likelihood of clinical benefit with immunotherapy alone. The gray zone is the PD-L1 range of 1% to 49%, as the benefits of ICI ...